Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bryan T Mott

Showing results (21-30 of 53) with videos related to

Pageof 6
Sort By:
Journal of Medicinal Chemistry|November 14, 2009
Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol proteaseAjit Jadhav, Rafaela S Ferreira, Carleen Klumpp, et al.
The American Journal of Tropical Medicine and Hygiene|December 4, 2013
In vitro screening of compounds against laboratory and field isolates of human hookworm reveals quantitative differences in anthelmintic susceptibilityRebecca S Treger, Joseph Otchere, Martin F Keil, et al.
Journal of Medicinal Chemistry|December 2, 2011
Malaria-infected mice are completely cured by one 6 mg/kg oral dose of a new monomeric trioxane sulfide combined with mefloquineRachel D Slack, Bryan T Mott, Lauren E Woodard, et al.
Bioorganic & Medicinal Chemistry Letters|April 1, 2011
Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk)Andrew S Rosenthal, Cordelle Tanega, Min Shen, et al.
Journal of Medicinal Chemistry|June 15, 2010
Complementarity between a docking and a high-throughput screen in discovering new cruzain inhibitorsRafaela S Ferreira, Anton Simeonov, Ajit Jadhav, et al.
Bioorganic & Medicinal Chemistry Letters|October 20, 2009
Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk)Bryan T Mott, Cordelle Tanega, Min Shen, et al.
Blood Advances|February 9, 2021
Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclaxBlake S Moses, Samantha McCullough, Jennifer M Fox, et al.
Oncotarget|January 16, 2016
Artemisinin-derived dimer ART-838 potently inhibited human acute leukemias, persisted in vivo, and synergized with antileukemic drugsJennifer M Fox, James R Moynihan, Bryan T Mott, et al.
Scientific Reports|November 25, 2016
mQC: A Heuristic Quality-Control Metric for High-Throughput Drug Combination ScreeningLu Chen, Kelli Wilson, Ian Goldlust, et al.
Oncogene|April 17, 2022
Targeting oncometabolism to maximize immunotherapy in malignant brain tumorsJoshua D Bernstock, Kyung-Don Kang, Neil V Klinger, et al.
Pageof 6

Showing results (21-30 of 53) with videos related to

Sort By:
Pageof 6
Journal of Medicinal Chemistry|November 14, 2009
Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol proteaseAjit Jadhav, Rafaela S Ferreira, Carleen Klumpp, et al.
The American Journal of Tropical Medicine and Hygiene|December 4, 2013
In vitro screening of compounds against laboratory and field isolates of human hookworm reveals quantitative differences in anthelmintic susceptibilityRebecca S Treger, Joseph Otchere, Martin F Keil, et al.
Journal of Medicinal Chemistry|December 2, 2011
Malaria-infected mice are completely cured by one 6 mg/kg oral dose of a new monomeric trioxane sulfide combined with mefloquineRachel D Slack, Bryan T Mott, Lauren E Woodard, et al.
Bioorganic & Medicinal Chemistry Letters|April 1, 2011
Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk)Andrew S Rosenthal, Cordelle Tanega, Min Shen, et al.
Journal of Medicinal Chemistry|June 15, 2010
Complementarity between a docking and a high-throughput screen in discovering new cruzain inhibitorsRafaela S Ferreira, Anton Simeonov, Ajit Jadhav, et al.
Bioorganic & Medicinal Chemistry Letters|October 20, 2009
Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk)Bryan T Mott, Cordelle Tanega, Min Shen, et al.
Blood Advances|February 9, 2021
Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclaxBlake S Moses, Samantha McCullough, Jennifer M Fox, et al.
Oncotarget|January 16, 2016
Artemisinin-derived dimer ART-838 potently inhibited human acute leukemias, persisted in vivo, and synergized with antileukemic drugsJennifer M Fox, James R Moynihan, Bryan T Mott, et al.
Scientific Reports|November 25, 2016
mQC: A Heuristic Quality-Control Metric for High-Throughput Drug Combination ScreeningLu Chen, Kelli Wilson, Ian Goldlust, et al.
Oncogene|April 17, 2022
Targeting oncometabolism to maximize immunotherapy in malignant brain tumorsJoshua D Bernstock, Kyung-Don Kang, Neil V Klinger, et al.
Pageof 6